Hinge Health heads into its Q2 earnings print with an unusually wide gap between bearish positioning and bullish analyst conviction.
The most striking feature of the current setup is how aggressively short sellers have retreated. Short interest peaked near 9.2 million shares in early July and has since fallen by more than a third, dropping to 15.3% of the free float. That's still a high absolute level, but the direction of travel is firmly lower — down 17.8% over the past month. Borrow conditions have eased dramatically to match: availability has surged above 2,500%, meaning the lending pool is far from constrained, and the cost to borrow is a negligible 0.47%. The borrow market offers no squeeze catalyst here. Options positioning tells a different story, however. The put/call ratio has jumped to 0.86, more than two and a half standard deviations above its 20-day average of 0.55 — the most defensive options posture on record outside of last year's extreme readings. Traders are paying up for downside protection even as short sellers exit.
That tension — retreating shorts, elevated hedging — reflects a genuine debate about valuation. The bull case is anchored in execution: revenue projections are rising, AI-driven clinical tools are showing demonstrable cost savings for payers, and the company has expanded into women's health as a new growth vector. Analysts have responded in kind. Morgan Stanley lifted its target to $108 from $72 in mid-July, and Barclays moved to $97 from $70 in the same week. Canaccord and Keybanc both raised targets above $100. The consensus mean now sits at $92.67, implying roughly 17% upside to the current $79.42 close. Bears counter that management has flagged go-to-market capacity as the primary constraint on growth, HingeSelect is still early-stage, and the post-IPO lockup expiry creates potential supply pressure. Baird, holding a Neutral, only moved its target to $65 — well below where the stock trades today — signalling that not everyone on the Street is convinced the momentum is sustainable at current multiples. The PE multiple has compressed about 15% over the past 30 days, suggesting the market is already asking harder questions about the earnings power behind the growth story.
Ownership data adds a wrinkle. CEO and co-founder Daniel Perez received a large equity award in late July but simultaneously sold 509,000 shares for roughly $37.9 million at $74.31 — below the current price, suggesting the sale preceded the recent rebound. Insight Holdings, a 10% owner, also sold nearly $16 million of stock at prices around $90 in early July, before the stock pulled back. BlackRock, by contrast, added over 2 million shares in the June quarter, bringing its stake to 3.9% — a meaningful institutional vote of confidence from a passive-to-active crossover buyer. Two prior earnings events in 2026 both produced positive reactions: the June print moved the stock 3.1% on the day and 6.8% over five sessions, while the May event delivered a 7.7% single-day gain.
The print will test whether HNGE's revenue trajectory and early HingeSelect adoption data are enough to justify analyst targets that now cluster between $90 and $108 — and whether the options market's defensive posture was prescient or premature.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
